CLOVERNA, Inc.
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
CLOVERNA is a next-generation RNA medicine company unlocking the dark genome to develop first-in-class therapeutics for neurodegenerative diseases and cancer. Our proprietary DIRAC (Direct RNA Activity Capture)platform uses CRISPR/dCas13 to screen non-coding RNA interactions—including RNA-RNA and RNA-protein networks—in patient-derived models. Unlike RNA-seq or AI-based approaches, DIRAC captures structurally complex, disease-driving RNA targets that are otherwise inaccessible. This enables de novo discovery of RNA drug targets for ASOs, RNA degraders, and other modalities. CLOVERNA’s lead programs include CLV-201, an ASO for sporadic ALS, and CLV-301, a PD-1 pre-mRNA modulator for immunotherapy-resistant cancers. Both are advancing through IND-enabling studies. We are raising a $5M seed round to support IND filings and U.S. operations, and welcome discussions with investors and pharma partners for co-development, licensing, and platform collaborations.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}